Subclinical lesions and donor-specific antibodies in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen followed by early conversion to sirolimus

Transplantation

Volumn 99, Issue 11, 2015, Pages 2372-2381

  De Sandes Freitas, Tainá Veras ^a   Felipe, Cláudia Rosso ^a   Campos, Érika Fernandes ^b   De Lima, Maria Gerbasi ^b   Soares, Maria Fernanda ^c   De Franco, Marcello Fabiano ^a   Aguiar, Wilson Ferreira ^a   Tedesco Silva, Hélio ^a   Medina Pestana, José Osmar ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b AFIP   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS; ALLOANTIBODY; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; ATROPHY; BLACK PERSON; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DONOR; DONOR AGE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; ETHNICITY; FEMALE; FIBROSING ALVEOLITIS; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; INCIDENCE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; TUBULAR ATROPHY; ADVERSE EFFECTS; BIOPSY; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SUBSTITUTION; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEPHRITIS; ODDS RATIO; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ATROPHY; BIOMARKERS; BIOPSY; CALCINEURIN INHIBITORS; CHI-SQUARE DISTRIBUTION; DRUG SUBSTITUTION; FEMALE; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRITIS; ODDS RATIO; PROTEINURIA; RISK FACTORS; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84944101412     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000748     Document Type: Article

References (23)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor neph-rotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78(4):557-565.
2. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-2575.
3. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876-1885.
4. Rush D, Arlen D, Boucher A, et al. Lack ofbenefit ofearly protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007;7(11):2538-2545.
5. Heilman RL, Cortese C, Geiger XJ, et al. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. Transplantation. 2012;93(1):47-53.
6. Silva HT, Felipe CR, Garcia VD, et al. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant. 2013;13(12):3155-3163.
7. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant. 2004;4(11):1776-17785.
8. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant. 2012;12(5):1192-1198.
9. Kamar N, Del Bello A, Congy-Jolivet N, et al. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant. 2013;27(3):455-462.
10. Croze LE, Tetaz R, Roustit M, et al. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. Transpl Int. 2014;27(8):775-783.
11. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal al-lograft pathology: updates and future directions. Am J Transplant. 2008; 8(4):753-760.
12. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272-283.
13. Beimler J, Zeier M. Borderline rejection after renal transplantation-to treat or not to treat. Clin Transplant. 2009;23(Suppl 21):19-25.
14. Ruiz San Millan JC, López-Hoyos M, Segundo DS, et al. Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. Transpl Int. 2014;27(8):847-856.
15. Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation. Front Immunol. 2012;3:228.
16. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant. 2009;9(5):998-1005.
17. Stegall MD, Raghavaiah S, Gloor JM. The (re)emergence of B cells in organ transplantation. Curr Opin Organ Transplant. 2010;15(4):451-455.
18. Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol. 2010;159(2):199-207.
19. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326-2333.
20. Naesens M, Lerut E, Damme BV, et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant. 2007;7(9):2114-2123.
21. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011;79(8):897-907.
22. Rangan GK. Sirolimus-associated proteinuria and renal dysfunction. Drug Saf. 2006;29(12):1153-1161.
23. Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol. 2009;20(12):2490-2492.